We believe Bayer has a Morningstar economic moat rating of none. Despite some competitive advantages in its healthcare and crop science businesses when analyzed in isolation, we think the company's returns on invested capital have been weighed down by its $63 billion acquisition of Monsanto in 2018 and will remain below the cost of capital over the next 10 years or so.
Several drugs, including recently launched cancer drugs and late-stage pipeline asset asundexian, hold potential for further gains and have relatively steady pricing power partly based on excellent clinical data.
Generic Xarelto and Eylea entry in various territories over the near term will put accelerating pressure on Bayer's revenue and profit margins.
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.40 | 25.71 | 9.22 |
Price/Book Value | 1.59 | 1.16 | 1.88 |
Price/Sales | 1.04 | 0.69 | 2.53 |
Price/Cash Flow | 32.47 | 7.83 | 10.46 |
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.67 | 1.19 | 0.85 |
Current Ratio | 1.04 | 1.85 | 1.27 |
Interest Coverage | 0.27 | 3.59 | 2.36 |
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 4.50% | 0.97% | 8.46% |
Return on Equity (Normalized) | 16.50% | 2.27% | 19.70% |
Return on Invested Capital (Normalized) | 9.34% | 1.92% | 12.66% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|@!k%CH$ | LOCK|fQ< | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|^#vP?& | LOCK|^J | $623B | |||
| AbbVie Inc
ABBV
| LOCK|#yLt%$# | LOCK|&! | $459B | |||
| Merck & Co Inc
MRK
| LOCK|?Y%hm%@ | LOCK|tzf | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|PDg#@!Q# | LOCK|%s | $334B | |||
| Novartis AG ADR
NVS
| LOCK|Nt<>!J&K | LOCK|@? | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|R<CX>BG | LOCK|ZWZ | $252B | |||
| Amgen Inc
AMGN
| LOCK|xW%y>>R | LOCK|z& | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|>SR^S^? | LOCK|>! | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|z#XVNB | LOCK|@& | $167B |
United States